US 11,911,374 B2
Methods and uses for treating cancer
Manuel Hidalgo Medina, Boston, MA (US)
Assigned to NELUM CORPORATION, Durham, NC (US)
Filed by NELUM CORPORATION, Research Triangle Park, NC (US)
Filed on Jan. 20, 2021, as Appl. No. 17/153,345.
Application 17/153,345 is a continuation of application No. PCT/US2020/070080, filed on May 28, 2020.
Claims priority of provisional application 62/853,842, filed on May 29, 2019.
Prior Publication US 2022/0071982 A1, Mar. 10, 2022
Int. Cl. A61K 31/4545 (2006.01); A61K 31/337 (2006.01); A61K 31/4355 (2006.01); A61K 31/454 (2006.01); A61K 31/501 (2006.01); A61K 31/502 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/7068 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4545 (2013.01) [A61K 31/337 (2013.01); A61K 31/4355 (2013.01); A61K 31/454 (2013.01); A61K 31/501 (2013.01); A61K 31/502 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/7068 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 26 Claims
OG exemplary drawing
 
1. A method for treating a subject having a cancerous tumor, the method comprising
transient administration of TAK-441 as a hedgehog inhibitor (HHI) to the subject in combination with one or more additional cancer therapies,
wherein the one or more additional cancer therapies are administered in one or more cycles of treatment, wherein the one or more cycles of treatment include a treatment regimen comprising:
(a) administration of TAK-441 prior to administration of the one or more additional cancer therapies;
(b) administration of the one or more additional cancer therapies; and
(c) a repeat of step (a) and step (b) until the one or more cycles of treatment are complete; and
wherein the administration of TAK-441 does not continue throughout all cycles of treatment.